CMS seeks comment on Natrecor

The Centers for Medicare and Medicaid Services (CMS) is seeking public comment on a proposed determination to deny reimbursement for Natrecor nesiritide to treat chronic heart failure (CHF), an off-label use. The proposed decision would not change coverage of Natrecor for acutely decompensated heart failure, for which the recombinant B-type natriuretic peptide (BNP) vasodilator is approved. CMS will make a final decision following a 90-day public comment period. ...